请根据标普全球市场情报公司的数据的报告，2018年，大型制药公司默克( Merck ）的股价上涨了35.8%。其抗癌药物 Keytruda 的持续成功是该公司去年良好业绩的主要推动因素。
Shares of Merck & Co. (NYSE: MRK), a big pharmaceutical company, climbed 35.8% in 2018, according to data from S&P Global Market Intelligence. Continued success with its lead drug, Keytruda, was the main driver behind this stock's impressive performance last year.
根据标普全球市场情报公司( S 2018年，大型制药公司默克( Merck 其主要药物 Keytruda 的持续成功是该公司去年令人印象深刻业绩的主要推动因素。
Merck's shares began 2018 from a low point after the company made investors nervous by pulling a European application for its PD-1 checkpoint inhibitor, Keytruda, in late 2017. It turns out there wasn't anything to worry about. By the end of 2018, it was clear that Keytruda's dominance in the lung cancer arena will drive sales into the clouds.
默克的股票从2018年的低点开始，此前该公司在2017年底撤回其 PD-1检查点抑制剂 Keytruda 的欧洲申请，令投资者感到紧张。事实证明没有什么值得担心的。到2018年底，很明显Keytruda 在肺癌领域的主导地位将推动销售进入云端。
Lung cancer isn't the most common malignancy, but it claims more lives than any other. Around 85% of all lung cancer cases are of the non-small cell lung cancer (NSCLC) variety. Merck outperformed its big pharma peers by a mile last year because nearly all U.S. patients diagnosed with NSCLC will receive Keytruda on its own or in combination with standard chemotherapy going forward.
肺癌不是最常见的恶性肿瘤，但它声称比其他任何肿瘤都要多。约85%的肺癌病例属于非小细胞肺癌（ NSCLC ）品种。默克公司去年的表现要好于其他大型药企公司一英里，因为几乎所有被诊断为非小细胞非小细胞肺癌（NSCLC）的美国患者都将单独接受 Keytruda 治疗，或者联合标准化疗。
本文未完，继续阅读请访问汇众官网：www.investank.com/news/detail/130365?s=p0002
